Title :
Effects of platelets-derived growth factor receptor inhibitor on radiosensitivity of glioma cells
Author :
Fenju Liu ; Haiyan Liu ; Jiahua Yu ; Saijun Fan ; Xueqin Yang ; Zhiqiang Sun ; Jinping Yu
Author_Institution :
Dept. of Radiobiol., Soochow Univ., Suzhou, China
Abstract :
In present study, we investigated the mechanism of AG1295, a platelets-derived growth factor receptor (PDGFR) inhibitor, on radiosensitivity of the glioma cell line SHG-44. AG1295 induced a dose dependent cytotoxicity in the glioma cell line evidenced by MTT assay and the trypan blue dye exclusion method. Sensitization to ionizing radiation of SHG-44 was observed when pretreated with AG1295. Radiosensitization reached a peak at 24h after radiation. AG1295 markedly downregulated the expression of PDGFRa, but had little effect on the expression of PDGFRp. Flow cytometer assay revealed that AG1295 increased the G1 and G2 phases of the cell cycle, and Western blotting showed decreased cyclin B1 and cyclin D1 expression. AG1295 shows radiosensitizing effects on the SHG-44 glioma cells through a mechanism involving redistribution of the cell cycle by promoting cells to enter the radiation-sensitive G1 phase and G2 phase and inhibition of sublethal damage repair.
Keywords :
biological effects of ionising radiation; cellular effects of radiation; dosimetry; toxicology; AG1295; MTT assay; PDGFRα; PDGFRβ; Western blotting; cyclin B1 expression; cyclin D1 expression; dose dependent cytotoxicity; flow cytometer assay; glioma cell line SHG-44; ionizing radiation; platelet-derived growth factor receptor inhibitor; radiation-sensitive G1 phase; radiation-sensitive G2 phase; radiosensitization; radiosensitizing effects; sublethal damage repair; time 24 h; trypan blue dye exclusion method; Cancer; Drugs; Inhibitors; Proteins; Radiation effects; Sensitivity; Tumors; AG1295; Cell cycle; SHG-44; irradiation;
Conference_Titel :
Human Health and Biomedical Engineering (HHBE), 2011 International Conference on
Conference_Location :
Jilin
Print_ISBN :
978-1-61284-723-8
DOI :
10.1109/HHBE.2011.6027954
